Glenmark Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 1631.4, up 0.98% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.38% on the day, quoting at 25199.55. The Sensex is at 82711.36, up 0.39%. Glenmark Pharmaceuticals Ltd has risen around 18.07% in last one month.

Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has risen around 4.47% in last one month and is currently quoting at 21948, up 0.45% on the day. The volume in the stock stood at 3.64 lakh shares today, compared to the daily average of 9.49 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 1637.3, up 1.11% on the day. Glenmark Pharmaceuticals Ltd is up 35.62% in last one year as compared to a 8.05% spurt in NIFTY and a 11.69% spurt in the Nifty Pharma index.

The PE of the stock is 26.14 based on TTM earnings ending March 25.

Powered by Capital Market - Live News

Co-developed with global oncology leader BeOne Medicines, zanubrutinib will be marketed under the brand name Brukinsa. It is the first and only Bruton?s tyrosine kinase (BTK) inhibitor approved in India for five types of B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenstr?m macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL).

Globally, Brukinsa is approved in over 70 countries, backed by robust clinical evidence from pivotal trials such as Alpine, Aspen, and Sequoia. The drug has shown a strong safety profile, high response rates, and durable disease control.

With one Indian diagnosed with blood cancer every five minutes and around 70,000 deaths annually, Brukinsa addresses a critical treatment gap. Its flexible dosing (once or twice daily) supports personalized care. In the Alpine study for relapsed/refractory CLL, Brukinsa reported significantly fewer serious cardiac events (1.9% vs 7.7%) and lower treatment discontinuation (0.3% vs 4.3%) compared to ibrutinib.

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.

On a consolidated basis, Glenmark Pharmaceuticals reported net profit of Rs 4.65 crore in Q4 March 2025 as against net loss of Rs 1218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals has announced the upcoming launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI).

Zanubrutinib will be marketed in India under the brand name BRUKINSA?, an innovative therapy developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. BRUKINSA is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenstr?m macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL).

Globally, BRUKINSA is approved in more than 70 countries, supported by compelling clinical evidence from pivotal trials including ALPINE, ASPEN, and SEQUOIA. This extensive clinical program underscores BRUKINSA's proven efficacy, strong safety profile, and broad therapeutic value.

The introduction of BRUKINSA brings an innovative treatment option at a time when India continues to face a significant burden from serious and difficult-to-treat haematological malignancies. According to various sources, someone in India is diagnosed with blood cancer every five minutes, and an estimated 70,000 people die from the disease each year. BRUKINSA addresses a critical unmet need with its differentiated pharmacological profile, demonstrating high response rates and durable disease control across multiple B-cell malignancies as shown in pivotal clinical trials. BRUKINSA's flexible dosing regimen (once or twice daily) supports personalized care.1 In the head-to-head ALPINE study in relapsed/refractory chronic lymphocytic leukemia, BRUKINSA demonstrated a lower rate of serious cardiac events (1.9% vs. 7.7%) and fewer treatment discontinuations due to cardiac issues (0.3% vs. 4.3%) compared with ibrutinib.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 23 May 2025, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News